The estimated Net Worth of William J Peters is at least 14.1 百万$ dollars as of 31 July 2024. Mr. Peters owns over 10,282 units of Amphastar Pharmaceuticals Inc stock worth over 4,704,632$ and over the last 10 years he sold AMPH stock worth over 7,421,976$. In addition, he makes 1,957,020$ as Chief Financial Officer、 Senior Vice President、 Treasurer and President of International Medication Systems、 Limited at Amphastar Pharmaceuticals Inc.
William has made over 52 trades of the Amphastar Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 10,282 units of AMPH stock worth 208,005$ on 31 July 2024.
The largest trade he's ever made was selling 60,743 units of Amphastar Pharmaceuticals Inc stock on 6 September 2023 worth over 3,143,450$. On average, William trades about 8,486 units every 39 days since 2015. As of 31 July 2024 he still owns at least 104,385 units of Amphastar Pharmaceuticals Inc stock.
You can see the complete history of Mr. Peters stock trades at the bottom of the page.
William J. Peters serves as Chief Financial Officer, Senior Vice President, Treasurer and President of International Medication Systems, Limited of the Company. Mr. Peters has served as our Chief Financial Officer, Senior Vice President and Treasurer since April 2014 and as President of International Medication Systems, Limited (Amphastar Pharmaceutical’s subsidiary company) since March 2016. Mr. Peters previously served as Executive Vice President and Chief Financial Officer of Hi-Tech Pharmacal Co., Inc., or Hi-Tech, from August 2013 to April 2014 and Vice President and Chief Financial Officer at Hi-Tech from May 2004 to August 2013. From September 2003 to May 2004 he was Vice President of Corporate Development at Hi-Tech. From 2001 to 2003 Mr. Peters was the Director, Financial Evaluations for the Medco Health Solution subsidiary of Merck & Co., Inc., or Merck & Co., and Manager of Corporate Financial Analysis and Pharmaceutical Economics at Merck & Co. from 1998 to 2001. During his seven year career at Merck & Co., he also served as Manager of Treasury Planning and Analysis. He began his career in General Electric’s Financial Management Program at its Aerospace division, where he later held positions in financial analysis and internal auditing. He earned an M.B.A. from The Wharton School of Business, The University of Pennsylvania and a B.S. in Business Administration from Bucknell University.
As the Chief Financial Officer、 Senior Vice President、 Treasurer and President of International Medication Systems、 Limited of Amphastar Pharmaceuticals Inc, the total compensation of William Peters at Amphastar Pharmaceuticals Inc is 1,957,020$. There are 3 executives at Amphastar Pharmaceuticals Inc getting paid more, with Jack Zhang having the highest compensation of 5,969,740$.
William Peters is 52, he's been the Chief Financial Officer、 Senior Vice President、 Treasurer and President of International Medication Systems、 Limited of Amphastar Pharmaceuticals Inc since 2016. There are 14 older and 2 younger executives at Amphastar Pharmaceuticals Inc. The oldest executive at Amphastar Pharmaceuticals Inc is Richard Koo, 79, who is the Independent Director.
William's mailing address filed with the SEC is C/O AMPHASTAR PHARMACEUTICALS, INC., 11570 6TH STREET, RANCHO CUCAMONGA, CA, 91730.
Over the last 10 years, insiders at Amphastar Pharmaceuticals Inc have traded over 72,457,295$ worth of Amphastar Pharmaceuticals Inc stock and bought 66,100 units worth 921,987$ . The most active insiders traders include Jack Y.Luo Mary Z. Zhang、Richard K Prins、William J Peters. On average, Amphastar Pharmaceuticals Inc executives and independent directors trade stock every 11 days with the average trade being worth of 1,459,051$. The most recent stock trade was executed by Floyd F. Petersen on 5 September 2024, trading 3,000 units of AMPH stock currently worth 139,410$.
amphastar pharmaceuticals, inc., headquartered in rancho cucamonga, california, established in 1996, is a recognized specialty pharmaceutical company that uses state-of-the-art, cgmp compliant facilities to develop, manufacture, and market injectable and inhalation products. in addition to the corporate headquarters, amphastar has five manufacturing facilities located in the united states, china and europe along with a state-of-the-art new drug research center. amphastar and its subsidiaries each have their own distinct focus that they skillfully bring together to meet the varied needs of the pharmaceutical industry. we currently produce approximately 15 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. amphastar’s long-standing relationship with the major group purchasing organizations and drug wholesalers in the u.s. enables it to establish significant market share upon the int
Amphastar Pharmaceuticals Inc executives and other stock owners filed with the SEC include: